HUPA-UCM diabetes dataset.

This dataset provides a collection of Continuous Glucose Monitoring (CGM) data, insulin dose administration, meal ingestion counted in carbohydrate grams, steps, calories burned, heart rate, and sleep quality and quantity assessment ac- quired from 25 people with type 1 diabetes mellitus (T1DM). CGM data was acquired by FreeStyle Libre 2 CGMs, and Fitbit Ionic smartwatches were used to obtain steps, calories, heart rate, and sleep data for at least 14 days. This dataset could be utilized to obtain glucose prediction models, hypoglycemia and hyperglycemia prediction models, and research on the relationships among sleep, CGM values, and the rest of the mentioned variables. This dataset could be used directly from the preprocessed version or customized from raw data. The data set has been used previously with different machine learning algorithms to predict glucose values, hypo, and hyperglycemia and to analyze influences among the features and the quality and quantity of sleep in people with T1DM.

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

OBJECTIVE: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. METHODS: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the conditional logit model. RESULTS: Three-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m(2), 41.8% received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55-85.08]) the most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29-82.26]). Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 160.31-1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and decreasing cardiovascular risk (WTP: €166.87 [88.63-843.09] and €154.30 [98.13-434.19], respectively). Physicians and patients were willing to pay €125.92 (73.30-622.75) and €24.28 (18.41-30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 (73.39-543.62) and €42.74 (23.89-61.77) to avoid nausea. CONCLUSION: Both patients and physicians in Spain and Portugal are willing to pay for the health benefits associated with improved diabetes treatment, the most important being to avoid hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became the third most valued attributes for physicians and patients, respectively.

Resultados a medio-largo plazo de pacientes con diabetes tipo 1 remitidos a una consulta monográfica de bombas de insulina / Mid-long term results on the evaluation of type 1 diabetes patients referred to an insulin pump clinic

OBJETIVO: Analizar la evolución a largo plazo de los primeros 69 pacientes con diabetes mellitus tipo 1 remitidos a una consulta monográfica de bombas de insulina durante el periodo 2005-2012, para valorar la iniciación de terapia con infusión subcutánea continua de insulina (ISCI). MATERIAL Y MÉTODOS: Estudio retrospectivo, observacional y unicéntrico de 69 pacientes candidatos a ISCI. Se analizaron los pacientes que no iniciaron ISCI (n = 18) y los que sí lo hicieron (n = 51). Se analizaron las siguientes variables: edad, sexo, duración de la enfermedad, indicación de ISCI, HbA1c, frecuencia de episodios de hipoglucemias severas, cetoacidosis diabética y tasa de retirada de la ISCI. RESULTADOS: El motivo principal para no iniciar ISCI fue el rechazo del paciente (49%), seguido por mejoría de control glucémico tras optimizar tratamiento con múltiples dosis de insulina (MDI) (33%). Las principales indicaciones de ISCI fueron: mal control (49%), seguido de mal control asociado a hipoglucemias no graves (27,5%). La HbA1c previa al inicio de ISCI fue de 8,6 ± 1,5%, con una reducción media de un 1% mantenida durante 5 años (p < 0,001), siendo el descenso superior si la HbA1c basal > 8%. Cinco (10%) pacientes interrumpieron el uso de ISCI tras 1-6 años de la terapia. CONCLUSIÓN: En nuestra práctica clínica uno de cada 4 pacientes remitidos para comenzar ISCI no inician finalmente la terapia. El cambio de MDI a ISCI se asoció con una reducción del 1% de la HbA1c durante los primeros 5 años, siendo mayor en los pacientes con peor control glucémico

OBJECTIVE: To analyse the first 69 type 1 diabetes patients referred to a specialist team between 2005 and 2012 in order to evaluate the indication for continuous subcutaneous insulin infusion (CSII). METHODS: Retrospective, observational, single centre study conducted on 69 adult patients evaluated for CSII. An analysis was made on patients who did not initiate CSII (n = 18) and patients who were treated with CSII (n = 51). Variables included: age, gender, duration of disease, indication for CSII, HbA1c, frequency of severe hypoglycaemia events, episodes of diabetic ketoacidosis, and pump discontinuation. RESULTS: The main reason for not initiating CSII was patient refusal (49%), followed by improving of glycaemic control (33%) after optimising with multiple daily injections (MDI) therapy. The most common CSII indications were: suboptimal glycaemic control (49%), and suboptimal glycaemic control with frequent non-severe hypoglycaemia (27.5%). Baseline HbA1c was 8.6 ± 1.5%, and there was a significant and sustained decrease of 1% over a 5 year period (P < .001), with this reduction being greater in patients with HbA1c > 8%. The use of CSII was stopped by 5 patients (10%) after 1 to 6 years. CONCLUSION: In our clinical practice one in four patients evaluated for CSII did not initiate it. The switch from MDI to CSII was associated with a 1% reduction in HbA1c over 5 years, being greater in patients with poor glycaemic control

Control glucemico en pacientes hospitalizados no criticos / Glycemic control in non-critial hospitalized patients

Conocer la prevalencia de hiperglucemia en pacientes ingresados, el grado de control glucemico, la tasa de hipoglucemias y el tratamiento utilizado. Material y métodos Estudio observacional de corte transversal. Resultados De 691 pacientes, 185 (26,7%) tenían (..) (AU)

Objectives: To assess in hospitalized patients the prevalence of hyperglycemia, degree of glycemiccontrol, rate of hypoglycemia, and treatment used. Patients and (..) (AU)

[Glycemic control in non-critical hospitalized patients]. / Control glucémico en pacientes hospitalizados no críticos.

OBJECTIVES: To assess in hospitalized patients the prevalence of hyperglycemia, degree of glycemic control, rate of hypoglycemia, and treatment used. PATIENTS AND METHODS: A prospective, observational study. RESULTS: Hyperglycemia was found in 185 (26.7%) of 691 patients, of whom 85% had been diagnosed with diabetes and 15% had no diabetes. Preprandial mean blood glucose was 169 mg/dL (95% CI 160-177). Control goals were achieved by 34.5% of patients (blood glucose ≤140 mg/dL). In 121 patients only sliding-scale regular insulin was used, while 64 patients received both basal and regular insulin. The mean daily insulin dose used was 19.5 units. Oral antidiabetics were given to 11.4% of patients. Thirteen patients (7%) experienced hypoglycemia (< 70 mg/dL), none of them severe. CONCLUSIONS: Glycemic control is not adequate in hospitalized patients, probably because of overuse of sliding scales and the low insulin doses used.